In 2025, Baiyunshan Pharmaceutical Holdings conducted an environmental assessment and disclosed corporate waste management data in accordance with recognized sustainability reporting standards.The company provided a breakdown of its waste by type (hazardous vs non-hazardous) and treatment method (recovery vs disposal), enabling greater transparency into its waste handling and environmental practices.
| Metric (tonnes) | 2025 | 2024 | 2023 | 2022-2019 |
|---|---|---|---|---|
Total Waste Generated | 48,659.68a | 56,553.53a | 54,299.78a | |
Total Waste Recovered | N/A | N/A | N/A | |
Total Hazardous Waste Generated | 1,636.93a | 1,219.79a | 1,088.03a | |
Non-Hazardous Waste Disposed | N/A | N/A | N/A |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2025, Baiyunshan Pharmaceutical Holdings generated a total of 48,660 metric tonnes of waste.a
Of this amount, 3.36% of Baiyunshan Pharmaceutical Holdings's total waste generated of was classified as hazardous waste, characterized by properties such as toxicity, flammability, corrosiveness, or reactivity that may pose risks to human health, ecosystems, or the environment.96.64% was identified as non-hazardous waste, generally considered less harmful and subject to lighter regulatory controls.a
Since 2023, Baiyunshan Pharmaceutical Holdings's total waste generation decreased by 10.39%, with an additional 13.96% decline in 2025, suggesting a consistent and deliberate effort to minimize waste generation at the source.a
Over the same period, the share of hazardous waste in Baiyunshan Pharmaceutical Holdings's total output increased by 67.89%, including a further 55.97% rise in 2025, suggesting a troubling upward shift toward more environmentally harmful waste streams that could raise compliance costs and environmental risks.a
Overall, Baiyunshan Pharmaceutical Holdings's waste and hazardousness trends are mixed or inconclusive. A more detailed review of its materials, industry standards, and operational changes would help clarify the net environmental impact of its waste strategy.a